Blood test may predict immunotherapy success in advanced cancers

NCT ID NCT06227728

First seen Jan 18, 2026 · Last updated May 23, 2026 · Updated 19 times

Summary

This study is observing 50 adults with advanced cancers (lung, breast, colorectal, liver, stomach) who are starting immunotherapy. Researchers will track ctDNA levels in the blood to see if changes can predict early whether the treatment is working. They will also look at other markers like PD-L1 and TMB. The goal is to improve how doctors monitor treatment response without relying only on scans.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Medical Genetics Institute

    NOT_YET_RECRUITING

    Ho Chi Minh City, Vietnam

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Medicine and Pharmacy at HCMC

    RECRUITING

    Ho Chi Minh City, Hồ Chí Minh, Vietnam

    Contact

Conditions

Explore the condition pages connected to this study.